A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis

A Phase 1b/2 Multiple-Dose Safety Study and Pharmacokinetic/ Pharmacodynamic Study of LY2189102 in Patients With Rheumatoid Arthritis

The purpose of this study is to examine the safety and efficacy of this antibody in participants with rheumatoid arthritis.

Part A of the study is an initial dose escalation phase

Part B of the study is a randomized allocation of the entire dosing group to parallel treatment assignments

Inclusion Criteria:

• diagnosis of rheumatoid arthritis
• regular use of methotrexate
• active rheumatoid arthritis

Exclusion Criteria:

• Juvenile Rheumatoid Arthritis
• evidence of tuberculosis
• women who are pregnant or become pregnant during study, or are breast-feeding